This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
by Zacks Equity Research
Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.
5 of the Best-Performing Biotech Stocks of 2017
by Arpita Dutt
With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).
Why is Corcept's Stock Up More Than 150% So Far This Year?
by Zacks Equity Research
We take a look at the factors that drove the phenomenal growth in share price of Corcept (CORT) in 2017.
Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies
by Zacks Equity Research
Merck's (MRK) three diabetes drugs get FDA approval as adjunct treatment to diet and exercise to improve glycemic control in patients with diabetes mellitus.
Dow 30 Stock Roundup: Nike Beats, Pfizer Hikes Dividend
by Swarup Gupta
The Dow traversed a choppy week even as the much vaunted tax legislation finally gained legislative approval
Biogen's Alzheimer's Drug Misses Goal in Interim Analysis
by Zacks Equity Research
Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs
by Arpita Dutt
This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.
What's Happening in Advanced Renal Cell Carcinoma Space?
by Zacks Equity Research
The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment of advanced RCC,
Top Research Reports for Pfizer, FedEx & Abbott
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), FedEx (FDX) and Abbott (ABT).
Pfizer's Leukemia Drug Gets FDA Nod in First-Line Setting
by Zacks Equity Research
Pfizer's (PFE) leukemia drug Bosulif receives FDA approval in first-line setting.
Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.
Pfizer Hikes Dividend, Announces $10B Share Buyback Plan
by Zacks Equity Research
Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.
Merck's Keytruda Misses Primary End Point for Gastric Cancer
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda misses the primary endpoint in a phase III study, which analyzed it as a second-line treatment for patients with advanced gastric adenocarcinoma.
Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations
by Zacks Equity Research
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
by Zacks Equity Research
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
by Zacks Equity Research
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
by Zacks Equity Research
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
by Zacks Equity Research
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Pfizer Reports Updated Data from Phase III Study on Ibrance
by Zacks Equity Research
Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.
Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?
by Zacks Equity Research
Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.
5 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.
3 Drug/Biotech Stocks in Focus on World AIDS Day
by Zacks Equity Research
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.